Islet Sciences Announces Important Study Published in Diabetes Titled "Immune Therapy Reducing ß-Cell Death in Type 1 Diabetes"

NEW YORK--(BUSINESS WIRE)--Islet Sciences, Inc. (OTCBB:ISLT), (ISLT) a clinical stage company engaged in the research, development and commercialization of therapeutics in the field of diabetes, announced today an important study published in Diabetes by the American Diabetes Association titled Immune Therapy and ß-Cell Death in Type 1 Diabetes. “This study is another validator of our approach to tackling this worldwide disease,” stated John Steel, Islet Sciences Chairman and Chief Executive Officer. “We continue to make solid important strides in executing our business strategy and this paper represents a clinical application of our licensed technology by leading scientists in the field of diabetes research."